Top 100 Companies by R&D Spending, 2026

What the R&D spending ranking measures

Corporate R&D spending measures how much a company commits to research, product development, engineering, clinical trials, software platforms, semiconductor design, manufacturing technology and future product pipelines. It is especially important in 2026 because the largest R&D budgets are tied to the AI build-out, cloud infrastructure, drug discovery, semiconductor process nodes, electric vehicles, autonomy, batteries and software-defined industrial systems.

The top of the list is not simply a list of the biggest companies by revenue or market capitalization. A company can be enormous but not especially R&D-intensive, while a smaller pharma, chip or biotech group may spend a much larger share of sales on research. The ranking is therefore most useful when read together with sector context.

Charts: the scale and sector structure of corporate R&D

The first chart shows why R&D spending is concentrated at the top: the gap between the first five companies and the rest of the table is large. The second chart groups the Top 100 by sector, showing that these companies are better understood through innovation capacity than through revenue or market value alone.

Methodology

The ranking uses corporate research and development investment reported in company financial accounts. The main source is the European Commission’s Joint Research Centre Industrial R&D Investment Scoreboard, which compiles economic and financial information for the world’s largest corporate R&D investors. The 2026 edition of this page uses the latest available complete Scoreboard dataset, based on financial year 2024 accounts published in the 2025 Scoreboard. The table is designed for analytical reading; formal research should use the downloadable Scoreboard file and company filings as the reference version.

R&D spending is shown in billions of euros and rounded to one decimal place. Company names are normalised for readability, while sector labels are grouped into broad categories: ICT software, ICT hardware, health, automotive, industrials, chemicals, and aerospace & defence. These sector groups are used to make the page easier to interpret; detailed accounting classifications can differ across companies and reporting jurisdictions.

The share figure in the table is calculated against the rounded Top 100 total used on this page. It is not a share of all global business R&D. The broader Scoreboard covers the world’s top 2,000 R&D investors, which together account for the great majority of business-funded R&D. The Top 100 table therefore captures the most visible part of global corporate research spending, but it does not capture all private R&D, smaller private firms, university research, public laboratories or defence programmes reported outside company accounts.

The main limitation is that R&D spending is an input measure. It tells us how much a company spends, not whether that spending produces valuable patents, successful drugs, better chips, safer cars or stronger software. Accounting rules also matter. Some companies expense R&D immediately, while others may capitalise parts of development spending. Pharmaceutical R&D is shaped by clinical trials and regulatory risk; software R&D is shaped by engineering talent, infrastructure and data; semiconductor R&D is tied to design, process technology and equipment. Direct comparison is useful, but it must be read with sector context.

The ranking should be read as a spending comparison, not as a measure of patent quality, product success, stock quality or future returns. It uses the latest complete Scoreboard dataset available for the 2026 page edition.

What this means for readers

This ranking helps readers understand where the future economy is being financed. A high R&D budget signals that a company is trying to build future capabilities, whether in AI, drugs, chips, vehicles, cloud infrastructure, diagnostics, industrial automation or materials. It also shows which sectors require heavy, repeated investment just to remain competitive.

For technology readers, the page shows why AI is not only a software trend. The companies at the top are investing in models, chips, cloud capacity, data centers, devices and developer ecosystems. For healthcare readers, the ranking explains why pharma companies require large research budgets even when near-term product launches are uncertain. For industrial readers, the table shows how automotive, aerospace, chemicals and manufacturing technology remain deeply research-driven.

The important caution is that more R&D does not automatically mean a better company, a safer investment or a stronger product pipeline. Large firms may spend more because they operate at greater scale, because regulation is costly, because existing products need renewal or because competition is intense. The best use of the ranking is to compare sectors, understand innovation concentration and identify which regions and industries are funding the next generation of technology.

Sources

The page prioritises official and primary sources. Company-level values are based on the European Commission / JRC Scoreboard framework. For formal research, the downloadable Scoreboard dataset and company filings should be used as the reference version.